Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients
- PMID: 21422334
- DOI: 10.1001/archdermatol.2011.23
Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients
Abstract
Objective: To investigate the diagnostic value of commercially available BP230 and BP180-NC16a enzyme-linked immunosorbent assays (ELISAs) in routine practice in patients with bullous pemphigoid (BP).
Design: Single-center retrospective study.
Setting: French academic dermatology department.
Patients: The study population comprised 138 patients, who were admitted from January 1998 through December 2008.
Interventions: Sera samples were analyzed by ELISA; clinical and immunopathological data were recorded from the patients' medical charts.
Main outcome measures: BP230 and BP180-NC16a ELISA scores were evaluated with respect to clinical characteristics (number of blisters, mucosal involvement, localized or generalized disease, and outcome) and routine indirect immunofluorescence (IF).
Results: Of the 138 study patients, 81 (59%) had a positive BP230 ELISA result and 119 (86%) had a positive BP180 ELISA result. There was no relationship between a positive ELISA BP230 result and the disease extent at diagnosis or the presence of mucosal involvement. Serum anti-basement membrane zone autoantibodies (indirect IF) were more frequently detected when the BP230 ELISA result was positive (P < .001). The median anti-basement membrane autoantibody titer as detected by indirect IF was higher in patients with a positive BP230 result (P < .001). The BP180 ELISA result was associated with disease extent at diagnosis as estimated by both the percentage of patients with extensive BP (P = .01) and the mean number of blisters (P = .03) but was not associated with mucosal involvement.
Conclusions: The currently available BP230 ELISA is a reliable although less-sensitive test than BP180 ELISA in BP, and its diagnostic added value compared with BP180 ELISA alone is approximately 5%. Our results support the predominant contribution of the BP230-specific autoantibodies to anti-basement membrane zone antibody titer as detected by indirect IF.
Comment in
-
ELISA instead of indirect IF in patients with BP: Comment on "Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid".Arch Dermatol. 2011 Mar;147(3):291-2. doi: 10.1001/archdermatol.2011.24. Arch Dermatol. 2011. PMID: 21422335 No abstract available.
Similar articles
-
Evaluation of the combination of BP180-NC16a enzyme-linked immunosorbent assay and BP230 enzyme-linked immunosorbent assay in the diagnosis of bullous pemphigoid.Indian J Dermatol Venereol Leprol. 2012 Nov-Dec;78(6):722-7. doi: 10.4103/0378-6323.102364. Indian J Dermatol Venereol Leprol. 2012. PMID: 23075641
-
ELISA instead of indirect IF in patients with BP: Comment on "Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid".Arch Dermatol. 2011 Mar;147(3):291-2. doi: 10.1001/archdermatol.2011.24. Arch Dermatol. 2011. PMID: 21422335 No abstract available.
-
Diagnostic accuracy of BP180 NC16a and BP230-C3 ELISA in serum and saliva of patients with bullous pemphigoid.Clin Exp Dermatol. 2015 Apr;40(3):324-30. doi: 10.1111/ced.12510. Epub 2014 Dec 5. Clin Exp Dermatol. 2015. PMID: 25476471
-
Bullous pemphigoid of childhood: autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood.Arch Dermatol. 2000 Apr;136(4):527-32. doi: 10.1001/archderm.136.4.527. Arch Dermatol. 2000. PMID: 10768652 Review.
-
BP180- and BP230-specific IgG autoantibodies in pruritic disorders of the elderly: a preclinical stage of bullous pemphigoid?Br J Dermatol. 2014 Aug;171(2):212-9. doi: 10.1111/bjd.12936. Epub 2014 Aug 5. Br J Dermatol. 2014. PMID: 24601973 Review.
Cited by
-
The significance of preclinical anti-BP180 autoantibodies.Front Immunol. 2022 Aug 8;13:963401. doi: 10.3389/fimmu.2022.963401. eCollection 2022. Front Immunol. 2022. PMID: 36003369 Free PMC article. Review.
-
Deciphering the Contribution of BP230 Autoantibodies in Bullous Pemphigoid.Antibodies (Basel). 2022 Jun 28;11(3):44. doi: 10.3390/antib11030044. Antibodies (Basel). 2022. PMID: 35892704 Free PMC article. Review.
-
Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches.Clin Rev Allergy Immunol. 2023 Dec;65(3):331-353. doi: 10.1007/s12016-023-08973-1. Epub 2023 Oct 28. Clin Rev Allergy Immunol. 2023. PMID: 37897588 Review.
-
Association of Transient Palmoplantar Keratoderma With Clinical and Immunologic Characteristics of Bullous Pemphigoid.JAMA Dermatol. 2019 Feb 1;155(2):216-220. doi: 10.1001/jamadermatol.2018.4084. JAMA Dermatol. 2019. PMID: 30484821 Free PMC article.
-
Rituximab therapy in pemphigus and other autoantibody-mediated diseases.F1000Res. 2017 Jan 27;6:83. doi: 10.12688/f1000research.9476.1. eCollection 2017. F1000Res. 2017. PMID: 28184292 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous